APSR2026-556

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP03-014
P86
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1217886-46904-APSR2026-556_Anti_IgLON5_Case_Report_final_440044.pdf
Format: PDF Only
10. Respiratory Neurobiology and Sleep
2

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

DR. SONIA DALAL - KALYAN HOSPITAL PULMONOLOGY VADODARA India
DR ABHINAV BHOSLE * KALYAN HOSPITAL PULMONOLOGY VADODARA India
 
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
DR ABHINAV
BHOSLE
abhinavbhosle@yahoo.com
+919898089310
51-60
India
Case Report
A novel case of IGLON-5 disease - case report
Maximum 25 words
Abstract Content
 
 
 
 
The first case of anti IGLON-5 disease was reported in 2014 with 60 reported cases till date. Pathophysiology is not fully understood but there is reported malfunction of brain stem, hypothalamus, hippocampus and tegmentum on autopsy report.
70/male, hypertensive, abnormal sleep behaviour, sleep talking, sleep walking, doing activities like bathing and talking over phone in sleep. Consulted a psychiatrist, worsening symptoms, started acting out dreams. Overnight polysomnography showed obstructive episodes, poorly structured N2 and leg and chin movements during apnoea event. Neurological examination revealed involvement of cerebellar, cranial nerves and speech. Routine blood investigation, MRI brain and CSF routine analysis - normal. EEG - mild slowing in theta waves. Auto immune encephalitis panel and serum paraneoplastic panel was negative. IGLON-5 antibodies turned out to be positive. Patient was treated with corticosteroids, rituximab, IVIg and positive airway pressure device.
Localization of tau deposits in hypothalamus, periaqueductal gray matter and tegmentum cause this tauopathy. Symptoms include sleep and gait abnormalities and bulbar and cognitive symptoms. Undifferentiated NREM, poorly structured N2 and movements during hypopneas are classical features. Presence of anti-IGLON-5 autoantibodies in serum or CSF is diagnostic. Treatment includes corticosteroids, immunotherapy, plasmapheresis and positive airway pressure devices. Anti-IGLON-5 disease should be kept as differential in conditions presenting as bulbar motor neuron disease with sleep abnormalities. Role of immunotherapy is yet to be established. Reference- Jane Werner et. al. Anti-IgLON5 Disease Neurol Neuroimmunol Neuroinflamm. 2021 Feb 2;8(2): e962.
 
 
Yes
No
 
JPG or JPEG or PNG format ONLY
Sleep apnoeas, neurodegenerative disorder, poorly structured N2
maximum 3 keywords and no abbreviations, separated by commas
 
236